# Radiopharmaceutical Theranostics Market

> Radiopharmaceutical Theranostics Market Research Report: Size, Share, Trend Analysis By Applications (Oncology, Cardiology, Neurology, Endocrinology), By Radioisotope (Fluorine-18 (18F), Carbon-11 (11C), Nitrogen-13 (13N), Gallium-68 (68Ga), By Modality (PET (Positron Emission Tomography), SPECT (Single-Photon Emission Computed Tomography), SPECT/CT (Single-Photon Emission Computed Tomography/Computed Tomography), PET/CT (Positron Emission Tomography/Computed Tomography), By Target Disease (Cancer, Cardiovascular Disease, Neurological Disorders, Endocrine Disorders) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 11.8%
- **2025:** USD 4.12 Billion
- **2035:** USD 12.55 Billion
- **Key Players:** Novartis AG, Curium Pharma, Lantheus Holdings, GE HealthCare, Telix Pharmaceuticals, Bayer AG, Eli Lilly (Point Biopharma), ITM Isotope Technologies

**Report ID:** MRFR/HC/25439-HCR · **Pages:** 128 · **Author:** Rahul Gotadki & Satyendra Maurya · **Last Updated:** September 17, 2026

**URL:** https://www.marketresearchfuture.com/reports/radiopharmaceutical-theranostics-market-27107

---

## Market Summary

## Radiopharmaceutical Theranostics Market Summary

The Radiopharmaceutical Theranostics Market reached USD 4.12 billion in 2025 and opens the forecast window at USD 4.60 billion in 2026, climbing to USD 12.55 billion by 2035 at a 11.8% CAGR. Two catalysts anchor that trajectory. The US FDA has now cleared multiple radioligand therapies for prostate and gastroenteropancreatic tumours, and the US Department of Energy Isotope Program has committed more than USD 100 million since 2022 to domestic actinium-225 and lutetium-177 production capacity [[1]](https://fda.gov)[[3]](https://isotopes.gov).

The field of oncology is moving away from single-purpose imaging tracers to matched pairs of isotopes, in which the same targeted molecule is labeled first for diagnosis and subsequently for treatment. Gallium-68 and fluorine-18 scans now routinely unlock access to Lu-177 treatment, replacing the traditional sequence of anatomic imaging followed by unguided systemic chemotherapy. In 2024, Novartis alone recorded radioligand franchise revenues of over USD 1.3 billion, a number that recognized targeted radionuclide therapy as a commercial category, not an academic one [[12]](https://novartis.com).

In North America, CMS pass-through payment and strong installed base of PET/CT drive approximately 45% of 2025 revenue. Asia-Pacific is the fastest-growing region with a CAGR of over 14.6% through 2035. Europe is the second largest bloc at nearly USD 1.19 billion, buoyed by the European Commission’s SAMIRA action plan for medical radioisotope security[[7]](https://energy.ec.europa.eu). Thus, the Radiopharmaceutical Theranostics Market will be far less U.S.-centric in 2035 than it is today.

## Key Report Takeaways

The bullets below summarise the highest-conviction findings across the Radiopharmaceutical Theranostics Market.

### • By Technology (Radioisotope)

- Lutetium-177 accounts for approximately 38% of 2025 global revenue, the single largest isotope position
- Actinium-225 alpha emitters post the steepest expansion at roughly 21.4% CAGR to 2035
- Gallium-68 diagnostic agents generated close to USD 0.61 billion in 2025

### • By Sector (Application)

- Oncology commands about 84% of Radiopharmaceutical Theranostics Market demand, led by prostate and neuroendocrine indications
- Neurology applications advance at approximately 12.9% CAGR as amyloid and tau agents mature.
- Cardiology contributed near USD 0.21 billion in 2025 from perfusion and amyloidosis workflows.

### • By Geography

- North America leads the Radiopharmaceutical Theranostics Market with roughly 45% revenue share.
- Asia-Pacific expands fastest at approximately 14.6% CAGR through 2035
- Middle East & Africa reached about USD 0.12 billion in 2025, concentrated in Gulf tertiary centres

## Market Size and Forecast (2021–2035)

Figures below are a combination of reported revenue of listed radiopharmaceutical producers, procedure volume data from national [nuclear medicine](https://www.marketresearchfuture.com/reports/nuclear-medicine-market-6674) societies, isotope shipment records from reactor and cyclotron operators and reimbursement claims analysis. Historical years are reconciled to business filings. Forecast years utilize indication-level penetration modeling. Radiopharmaceutical Theranostics Market.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Regulatory approvals of radioligand therapies | 2.1 | Global | Medium-term (2–4 yr) | [1] |
| Rising prostate and neuroendocrine tumour incidence | 1.8 | Global | Long-term (≥4 yr) | [2] |
| Reimbursement expansion and coding reform | 1.5 | North America, Europe | Short-term (≤2 yr) | [5] |
| Isotope production capacity investment | 1.4 | North America, Europe | Medium-term (2–4 yr) | [3] |
| PET/CT and SPECT/CT installed-base growth | 1.2 | Asia-Pacific | Long-term (≥4 yr) | [6] |
| Large-pharma acquisition and pipeline capital | 1.1 | Global | Short-term (≤2 yr) | [13] |
| Regulatory harmonisation programmes | 0.7 | Europe, MEA | Long-term (≥4 yr) | [7] |

### Approval Momentum Reshapes Standard of Care

Regulatory clearance has moved faster than most incumbents expected. The VISION trial reported a 4.0-month overall survival benefit that underpinned the 2022 FDA approval of Lu-177 vipivotide tetraxetan, and the 2025 label extension into pre-taxane settings widened the eligible US population by an estimated 40,000 patients annually [[8]](https://nejm.org)[[1]](https://fda.gov). Each label extension converts a salvage-line product into a mainstream one, which is why the Radiopharmaceutical Theranostics Market compounds faster than general oncology therapeutics.

### Isotope Supply Becomes a Policy Priority

Governments now treat medical isotopes as strategic infrastructure. The DOE Isotope Program's accelerator-based actinium-225 output rose several-fold between 2021 and 2025, and Canada's Bruce Power committed roughly CAD 100 million to lutetium-177 irradiation capacity [[3]](https://isotopes.gov)[[9]](https://brucepower.com). Supply, not clinical appetite, has been the binding constraint since 2023.

### Reimbursement Reform Unlocks Community Sites

Payment mechanics decide whether a hospital can afford to dose. CMS transitional pass-through status and the 2024 separate-payment rule for diagnostic radiopharmaceuticals above USD 630 per dose removed a bundling penalty that had suppressed adoption in outpatient departments [[5]](https://cms.gov). Community oncology networks, rather than academic centres, now represent the fastest-adding site category.

## Restraints

## Restraints Impact Analysis

Restraint percentages express directional drag on the headline growth rate. They are analyst-weighted and interact — logistics friction, for instance, amplifies the commercial effect of isotope scarcity across the Radiopharmaceutical Theranostics Market.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Short half-life and cold-chain logistics | −1.6 | Global | Long-term (≥4 yr) | [10] |
| Actinium-225 and enriched target scarcity | −1.3 | Global | Medium-term (2–4 yr) | [3] |
| Reimbursement gaps outside US and EU | −1.1 | Asia-Pacific, South America | Long-term (≥4 yr) | [11] |
| Radiopharmacy workforce and licensing bottlenecks | −0.9 | Global | Medium-term (2–4 yr) | [4] |
| Radioactive waste and facility compliance cost | −0.6 | Europe, MEA | Long-term (≥4 yr) | [7] |

### Physics Sets the Delivery Window

Gallium-68 decays with a 68-minute half-life and lutetium-177 with 6.6 days, so every dose is a perishable shipment scheduled against a named patient. Missed slots are unrecoverable revenue. Manufacturers report single-digit percentage batch wastage on long-haul routes, which effectively caps addressable geography around each production node [[10]](https://iaea.org).

### Alpha Emitters Remain Supply-Starved

Global actinium-225 availability has historically been measured in curies per year, sufficient for only a few thousand patient courses. Thorium-229 generator stock is finite, and accelerator routes require sustained capital [[3]](https://isotopes.gov). Until throughput multiplies, alpha-emitter pipelines will run ahead of the doses needed to commercialise them.

## Opportunities

## Radiopharmaceutical Theranostics Market Opportunities

### Decentralised Production Networks

Regional radiopharmacies sited within four hours of high-volume cancer centres convert logistics drag into competitive moat. Operators that pre-position licensed hot cells ahead of approvals will capture launch volume that competitors cannot physically serve, a structural advantage in the Radiopharmaceutical Theranostics Market.

### Beyond Prostate and Neuroendocrine Targets

FAP-, SSTR2-, and CAIX-directed candidates extend the paired imaging-and-treatment model into pancreatic, renal, and sarcoma settings. Roughly 90 radioligand programmes were in active clinical development as of 2025, and even modest conversion rates would broaden the revenue base materially [[13]](https://nature.com).

### Emerging-Market Build-Out

India, Brazil, Indonesia, and Saudi Arabia are commissioning cyclotrons and national isotope programmes with sovereign backing. India's Department of Atomic Energy supplies domestically produced Lu-177 at a fraction of imported cost, opening a value-tier segment that Western pricing models cannot address [[14]](https://dae.gov.in).

### Dosimetry-as-a-Service and Software Monetisation

Personalised dosimetry software, cloud dose-planning platforms, and outcome registries create recurring revenue independent of isotope margin. Vendors bundling quantitative SPECT analytics with dose supply can defend price as generic isotopes arrive, a business model still under-monetised in the Radiopharmaceutical Theranostics Market.

### Contract Manufacturing Capacity

Specialist CDMOs with radiological licences remain scarce. Every biotech without in-house hot-cell capability becomes a customer, and multi-year tolling contracts carry unusually high switching costs.

## Future Outlook

## Radiopharmaceutical Theranostics Market Future Outlook

### Alpha Emitters Move From Scarcity to Scale

Accelerator and generator capacity additions announced through 2025 should raise actinium-225 availability by an order of magnitude before 2030 [[3]](https://isotopes.gov). That single supply variable determines whether alpha therapy remains a niche or becomes the second growth engine of the Radiopharmaceutical Theranostics Market.

### Quantitative Dosimetry Becomes Standard Practice

Fixed-activity dosing will give way to patient-specific dose calculation as regulators and payers demand evidence of delivered absorbed dose. EANM guidance already pushes in this direction, and nuclear medicine theranostics workflows will increasingly resemble radiation oncology planning [[17]](https://eanm.org).

### Supply-Chain Regionalisation

Manufacturers are shifting from a handful of global plants to distributed nodes serving four-to-six-hour delivery radii. Capital intensity rises, but wastage falls, and launch geography widens — a trade most large players have already accepted [[10]](https://iaea.org).

### Payment Models Follow Outcomes

Value-based contracts tying reimbursement to progression-free survival are being piloted in European tenders. Should these spread, pricing power in the Radiopharmaceutical Theranostics Market will migrate toward developers holding the strongest registry evidence [[11]](https://who.int).

## Segment Insights

## Radiopharmaceutical Theranostics Market Segmentation

### By Radioisotope

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Lutetium-177 | 38% share | Approved prostate and NET therapies |
| Gallium-68 | USD 0.61 Billion | Companion diagnostic imaging |
| Fluorine-18 | 16% share | Widespread cyclotron availability |
| Iodine-131 | 11% share | Thyroid carcinoma standard of care |
| Actinium-225 | 21.4% CAGR | Alpha-emitter pipeline maturation |
| Yttrium-90 | 6% share | Hepatic radioembolisation |
| Others (Tc-99m, Cu-64, Pb-212) | 5% share | Emerging pairs and legacy imaging |

Lutetium-177 dominates because it is the only beta emitter with two approved, reimbursed, high-volume indications and a mature supply chain behind it. The Radiopharmaceutical Theranostics Market will stay Lu-177-weighted through at least 2030. Gallium-68 matters disproportionately relative to its revenue: no scan, no therapy, which makes diagnostic volume the leading indicator for therapeutic demand two quarters later.

### By Application

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Oncology — Prostate | 41% share | Label extension into earlier lines |
| Oncology — Neuroendocrine | USD 0.78 Billion | Established somatostatin-receptor pairs |
| Oncology — Other solid tumours | 15.8% CAGR | FAP and CAIX pipeline candidates |
| Neurology | 12.9% CAGR | Amyloid and tau imaging adoption |
| Cardiology | USD 0.21 Billion | Amyloidosis and perfusion studies |

[Prostate cancer](https://www.marketresearchfuture.com/reports/prostate-cancer-market-1580) carries the Radiopharmaceutical Theranostics Market on the strength of incidence, biomarker prevalence, and payer familiarity. Neuroendocrine tumours came first chronologically and still deliver the most durable per-patient economics, since treatment courses run four cycles with well-characterised outcomes.

### By End User

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals and academic centres | 57% share | Licensed hot labs and inpatient capacity |
| Specialty cancer centres | 19.4% CAGR | Dedicated dosing suites, faster throughput |
| Diagnostic imaging centres | USD 0.62 Billion | Companion scan volume |
| Research institutions | 6% share | Trial dosing and isotope development |

Source for all Section 9 tables: Market Research Future (MRFR) Analysis

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 45.0% share | Domestic Ac-225, community-site dosing |
| Europe | USD 1.19 Billion | SAMIRA implementation, reactor replacement |
| Asia-Pacific | 14.6% CAGR (2026–2035) | Cyclotron build-out, domestic isotope supply |
| South America | USD 0.16 Billion | Public-hospital nuclear medicine capacity |
| Middle East & Africa | 2.8% share | Gulf tertiary oncology centres |
| Total | USD 4.12 Billion | — |

Geographic concentration in the Radiopharmaceutical Theranostics Market reflects where reactors, cyclotrons, and reimbursement coincide rather than where cancer burden is highest.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| United States | 88% of regional revenue | CMS separate payment for high-cost doses |
| Canada | USD 0.19 Billion | Reactor-based Lu-177 irradiation capacity |
| Mexico | 13.1% CAGR | Private oncology network expansion |

Dominance here is manufactured, not inherited. The United States pairs the world's densest PET/CT fleet with a payment system that finally separates radiopharmaceutical cost from procedure bundling. At the same time, Canada contributes irradiation capacity that serves both domestic and export demand [[5]](https://cms.gov)[[9]](https://brucepower.com). The Radiopharmaceutical Theranostics Market in North America is increasingly limited by trained radiopharmacists rather than by patient demand.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 24% of regional revenue | Established academic dosing centres |
| United Kingdom | USD 0.17 Billion | NHS radioligand service commissioning |
| France | 15% of regional revenue | Domestic isotope production base |
| Italy | 12.4% CAGR | Regional oncology network adoption |

Europe's constraint is ageing infrastructure. Several research reactors that supply medical isotopes approach end-of-life this decade, and the SAMIRA action plan exists precisely to prevent a supply cliff [[7]](https://energy.ec.europa.eu). Germany's long-standing hospital-based compounding tradition gives it depth that newer entrants struggle to replicate quickly.

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | 34% of regional revenue | NMPA approvals and provincial cyclotron funding |
| Japan | USD 0.19 Billion | Ageing population, established SPECT base |
| India | 18.7% CAGR | Domestic Lu-177 production at low cost |
| Australia | 9% of regional revenue | ANSTO reactor isotope supply |

Growth across Asia-Pacific rests on import substitution. China and India both treat isotope self-sufficiency as industrial policy, which compresses landed cost and expands the treatable population far beyond what imported pricing allows [[14]](https://dae.gov.in). Japan supplies the region's most sophisticated imaging infrastructure, making it the natural site for early trials within the Radiopharmaceutical Theranostics Market.

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 62% of regional revenue | IPEN domestic radiopharmaceutical production |
| Argentina | USD 0.03 Billion | CNEA reactor and cyclotron network |
| Rest of South America | 13.6% CAGR | Private-sector imaging expansion |

Brazil anchors the region through IPEN's public production capability, which supplies subsidised doses to the SUS system [[15]](https://ipen.br). Currency volatility and import dependence for enriched targets remain the practical ceiling on faster adoption.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 38% of regional revenue | Vision 2030 oncology infrastructure |
| United Arab Emirates | USD 0.03 Billion | Medical tourism and tertiary centres |
| South Africa | 15.2% CAGR | NTP Radioisotopes production base |

Gulf states are buying capability outright, commissioning turnkey nuclear medicine departments inside new tertiary hospitals [[16]](https://moh.gov.sa). South Africa remains the continent's only meaningful producer, giving it disproportionate influence over sub-Saharan access.

## Competitive Benchmarking

## Competitive Benchmarking

High concentration at the therapeutic end, low at the diagnostic end. The top five participants are anticipated to account for 55–62% of global income, indicating an HHI of 900–1,200 — moderately concentrated overall, but effectively oligopolistic within licensed radioligand therapy. Barriers are physical. Radiological licences, hot cells and isotope contracts cannot be improvised. This is why entry into the Radiopharmaceutical Theranostics Market normally happens through acquisition.

| Company | Est. Revenue Share Range | Key Offerings for Radiopharmaceutical Theranostics Market | Strategic Positioning |
| --- | --- | --- | --- |
| Novartis AG | ~22–27% | Lu-177 PSMA and SSTR therapies, Ga-68 diagnostics | Category leader, vertically integrated |
| Curium Pharma | ~9–12% | Diagnostic tracers, Lu-177 supply, generators | Broadest production footprint |
| Lantheus Holdings | ~8–11% | PSMA PET agents, therapeutic pipeline | Diagnostic-first, therapy-expanding |
| GE HealthCare | ~6–9% | PET tracers, imaging systems, dose software | Equipment-plus-agent bundling |
| Telix Pharmaceuticals | ~4–6% | Prostate, renal, glioma imaging and therapy | Indication-focused challenger |
| Bayer AG | ~3–5% | Alpha-emitter therapy, targeted alpha pipeline | Early alpha-therapy incumbent |
| Eli Lilly (Point Biopharma) | ~3–5% | Lu-177 candidates, manufacturing capacity | Acquired capability, pipeline heavy |
| ITM Isotope Technologies | ~2–4% | Non-carrier-added Lu-177, SSTR therapy | Upstream isotope specialist |
| Eckert & Ziegler | ~2–4% | Isotope components, generators, CDMO | Picks-and-shovels supplier |
| Jubilant Radiopharma | ~2–3% | Diagnostics, radiopharmacy network | Distribution-led regional player |

## Recent News & Developments

## Recent News & Developments

- US FDA (March 2025): Expanded the Lu-177 PSMA label into pre-taxane metastatic castration-resistant prostate cancer, widening eligible US patients by roughly 40,000 per year [[1]](https://fda.gov)
- Eli Lilly (December 2023): Completed the USD 1.4 billion acquisition of Point Biopharma, adding Indiana manufacturing capacity and two late-stage radioligand candidates [[13]](https://nature.com)
- AstraZeneca (June 2023): Closed its USD 2.4 billion purchase of Fusion Pharmaceuticals, signalling large-pharma conviction in actinium-225 assets [[13]](https://nature.com)
- European Commission (February 2024): Advanced SAMIRA implementation with a coordinated plan addressing ageing reactor supply of medical isotopes [[7]](https://energy.ec.europa.eu)
- Bruce Power (September 2024): Began commercial lutetium-177 irradiation, adding a North American supply node outside the US [[9]](https://brucepower.com)
- Novartis (October 2025): Opened additional radioligand production capacity in Europe, targeting reduced dose-slot wait times [[12]](https://novartis.com)
- CMS (January 2025): Implemented separate payment for diagnostic radiopharmaceuticals exceeding USD 630 per dose in outpatient settings [[5]](https://cms.gov)
- India DAE/BRIT (July 2024): Scaled domestic Lu-177 output to supply national cancer centres at subsidised cost [[14]](https://dae.gov.in)

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Radiopharmaceutical Theranostics Market across isotopes, applications, end users, and five regions |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 11.8% (2026–2035) |
| Market Size Checkpoints | USD 4.12 B (2025); USD 4.60 B (2026); USD 7.19 B (2030); USD 12.55 B (2035) |
| Fastest Growing Segments | Actinium-225 (isotope); Specialty cancer centres (end user); Asia-Pacific (region) |
| Companies Profiled | Novartis, Curium, Lantheus, GE HealthCare, Telix, Bayer, Eli Lilly, ITM, Eckert & Ziegler, Jubilant Radiopharma |
| Valuation Currency | USD, constant 2025 basis |
| CAGR Driver Disclaimer | Driver and restraint impact percentages are directional analyst weightings, not additive components of the headline CAGR. |

## Frequently Asked Questions

**Q: What contractual terms matter most when procuring supply in the Radiopharmaceutical Theranostics Market?**
A: Prioritise guaranteed dose-slot allocation and batch-failure remedies over unit price. Half-life means an undelivered dose cannot be rescheduled cheaply, so service-level commitments carry more economic weight than discounts [10].

**Q: How should a hospital choose between beta and alpha emitters clinically?**
A: Beta emitters like Lu-177 suit larger, well-vascularised lesions; alpha emitters deliver higher energy over shorter ranges, favouring micrometastatic disease. Availability currently decides more cases than biology does [3].

**Q: What site-readiness investment does entry into the Radiopharmaceutical Theranostics Market require?**
A: Expect a licensed hot lab, shielded dosing rooms, waste-decay storage, and a radiation safety officer. Most centres budget 12–18 months from application to first patient dose [4].

**Q: Which due-diligence red flags matter when evaluating radioligand developers?**
A: Check secured isotope supply agreements and manufacturing licences before pipeline breadth. Promising molecules without contracted curies routinely miss launch timelines [13].

**Q: Are generics a real threat within the Radiopharmaceutical Theranostics Market?**
A: Yes, but slowly. Regulatory pathways for radiopharmaceutical generics are unsettled, and manufacturing barriers are physical rather than chemical, which delays erosion well past nominal patent expiry [1].

**Q: What non-oncology uses look most credible this decade?**
A: Cardiac amyloidosis imaging and neuroinflammation targets have the strongest evidence base. Both leverage existing scanner fleets, lowering the adoption barrier considerably [17].

**Q: How does dosimetry software change the vendor relationship?**
A: It converts a one-off dose sale into a platform relationship with recurring licence revenue. Centres that standardise on one planning system rarely switch, since staff training and registry data are sticky [17].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/radiopharmaceutical-theranostics-market-27107*